Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2).
Andreas WollenbergAndrew BlauveltEmma Guttman-YasskyMargitta WormC LyndeJean-Philippe LacourLynda SpelmanNorito KatohHidehisa SaekiY PoulinA LesiakLeon KircikS H ChoPedro Herranz PintoMichael J CorkKetty PerisL A SteffensenB BangA KuznetsovaT N JensenM L ØsterdalE L Simpsonnull nullPublished in: The British journal of dermatology (2020)
Tralokinumab monotherapy was superior to placebo at 16 weeks of treatment and was well tolerated up to 52 weeks of treatment.